AHA Scientific Sessions 2019 Daily News - Day 2

Need to charge your device? Visit the Charging Lounge in the HEART Hub or one of the charging stations in Grand Hall, Level 2, and in the Broad Street Atrium, Level 1. Sponsored by Amgen. TOP PICKS from the Program Chair AND Late-Breaking Science schedule 3 Inside Trials’ results suggest outside- the-box approaches to reduce CVD risk 5 ISCHEMIA clinical outcomes An initial invasive strategy of routine catheterization and revascularization did not demonstrate a reduction in risk for clinical events over 3.3 years of follow-up compared to an initial conservative strategy of optimal medical therapy for patients with stable ischemic heart disease (SIHD) and moderate to severe angina. ISCHEMIA (International Study of Comparative Effectiveness with Medical and Invasive Approaches) was the ScientificSessions.org #AHA19 SUNDAY Nov. 17, 2019 November 16-18, 2019 | Philadelphia, Pennsylvania DAILY NEWS See ISCHEMIA , page 13 S ix experts will discuss the importance of detecting peripheral artery disease early and initiating prompt, targeted care. The risk of developing coronary artery disease, heart attack or stroke is higher among an estimated 8.5 million Americans with PAD than in the general population. Those with PAD are also more likely to lose a limb. Yet, many people with PAD don’t know they have it. Some feel no pain, so they don’t seek medical advice. Others write off their symptoms to age. And in some cases, health care professionals miss the signs. “PAD is a common cardiovascular condition, yet it’s often underdiagnosed and undertreated,” said Geoffrey Session to highlight importance of detecting peripheral artery disease early, improved protocols See PAD , page 14 Echocardiographic screening of children may reduce burden of rheumatic heart disease E chocardiographic screening of children for subclinical rheumatic heart disease and secondary antibiotic prevention in affected children may reduce the burden in endemic regions, according to an abstract presented Saturday. In the study, researchers conducted a cluster-randomized comparison of echocardiographic A Sign of the Times for PAD: Stents, Drugs and Walk ‘n’ Roll 10:45 a.m.-Noon Sunday Main Event II UPCOMING SESSION Beyond the 2018 Cholesterol Guidelines Q&A with Neil J. Stone, MD, and Francine K. Welty, MD, PhD 11 See SCREENING , page 6 most anticipated trial at Scientific Sessions, said moderator Elliott Antman, MD, professor of medicine at Harvard Medical School in Boston. Conflicting trial results left the profession in equipoise over the most appropriate approach to treating patients with SIHD and angina. ISCHEMIA is the only trial to compare revascularization versus optimal medical therapy in patients with SIHD and moderate to severe angina, said Co-Principal Investigator Judith S. Hochman, MD, Harold Snyder Family Professor and associate director of cardiology and co- director of NYU-HHC Clinical and Translational Science Institute at New York University School of Medicine. ISCHEMIA is also the largest trial to compare the two treatment strategies in SIHD. Investigators randomized 5,179 patients with SIHD and moderate to severe angina to optimal medical therapy alone or in combination with routine coronary revascularization by PCI or CABG if feasible. Patients were followed for a mean of 3.3 years. Patients in earlier trials comparing invasive versus medical therapy had angiography prior to randomization, Hochman Researchers in “Results for the ISCHEMIA Trials: To Intervene or Not To Intervene” Late-Breaking Science session on Saturday found: • Initial invasive therapy compared to optimal medical therapy in patients with stable ischemia heart disease and moderate-severe ischemia did not reduce the risk for cardiovascular events. • Initial invasive therapy is more effective than optimal medical therapy in controlling angina and for QOL for patients with stable ischemic heart disease who have angina. • For patients with advanced chronic kidney disease and stable ischemic heart disease, an initial invasive therapy does not improve risk for cardiovascular events versus optimal medical therapy. ISCHEMIA Early intervention vs. conservative therapy can improve angina symptoms, quality of life for patients with SIHD and angina Hochman